期刊
JOURNAL FOR IMMUNOTHERAPY OF CANCER
卷 10, 期 4, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2021-004462
关键词
Oncolytic Virotherapy; Oncolytic Viruses; Adjuvants; Immunologic; Immunotherapy; Review
资金
- NIH-NCI [R01-CA194090]
- NIH-NIAID [R21-AI142387]
- ACS [RSG-17-047-01-MPC]
- Medical University of South Carolina
- University of New Mexico Health Sciences Center
- [NIH-K12-2GM088021]
Surgical removal of tumors is a front-line therapy for cancer, but often fails to eradicate the disease completely. To improve surgical outcomes, patients are often given non-curative treatments before surgery. Oncolytic virotherapy has been identified as potentially effective in the neoadjuvant setting.
Surgical removal of tumors remains a front-line therapy for many types of cancer. However, this treatment often fails to eradicate disease due to either recurrence of the original tumor or development of distant micrometastases. To address these challenges, patients are often given non-curative treatments presurgery with the intent of improving surgical outcomes. These treatments, collectively known as neoadjuvant therapies, have traditionally focused on the presurgical use of chemotherapeutics. Recently, however, a variety of immunotherapies have also been identified as potentially effective in the neoadjuvant setting. One of these immunotherapies is oncolytic virotherapy, whose clinical use has exploded with the Food and Drug Administration approval of Talimogene Laherparepvec. This review summarizes both the preclinical and clinical literature examining the use of oncolytic virotherapy in the neoadjuvant setting for different types of cancers and discusses some of the major questions that still need to be addressed in order for this unique use of immunotherapy to become clinically viable.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据